Looking at the contract, it is for a H5N8, clade 2.3.4.4b vaccine.
The current strain in North America is H5N1, clade 2.3.4.4b.
So I am confused. They are purchasing a vaccine for a disease that is currently not present, and the vaccine is based on a different strain than the one that is currently circulating in North America?
(maybe some cross immunity can be achieved, but is certainly not optimal, especially for a disease that is currently not present in humans).
Looking at the contract, it is for a H5N8, clade 2.3.4.4b vaccine.
The current strain in North America is H5N1, clade 2.3.4.4b.
So I am confused. They are purchasing a vaccine for a disease that is currently not present, and the vaccine is based on a different strain than the one that is currently circulating in North America?
(maybe some cross immunity can be achieved, but is certainly not optimal, especially for a disease that is currently not present in humans).
Can someone help me understand this all?
You’re on the ball Myra which makes me think if you need help understanding this there’s no hope for the rest of us! Lol